Every Peptide Explained (Human Studies Only)

Its trial asked whether people recovering from bowel surgery could tolerate solid food sooner. It didn’t measure muscle, and on that meal measure it found no clear advantage over placebo.

See the sources (2)

• Promoted for muscle growth and recovery. The FDA’s review of ipamorelin documents clinics promoting it that way.
• The trial studied people recovering from bowel surgery. Could ipamorelin help them tolerate solid food sooner? They weren’t measuring muscle growth.
• Compared with a placebo, a treatment without the active drug, it found no clear advantage on that meal measure.
• That result doesn’t tell us whether ipamorelin builds muscle. The trial simply wasn’t designed to answer that.

• FDA ipamorelin review (clinic promotion for muscle and recovery, PDF page 18)

Two controlled studies in healthy adults found it raised growth hormone and IGF-1. They didn’t establish that anyone built more muscle or recovered faster.

See the sources (2)

• Designed to keep growth hormone elevated for longer. A 2026 review describes it being promoted for muscle growth, fat metabolism and recovery.
• Two placebo-controlled studies in healthy adults: growth hormone and another growth-related hormone, IGF-1, went up. That’s a measurable effect.
• Those studies didn’t establish that participants built more muscle or recovered faster from training. A hormone result and a benefit you can feel are separate steps.

• 2026 review describing how it’s promoted · PubMed 41880199

In one small knee-pain report, 11 of 12 people who received BPC-157 alone said their pain improved. Neither of its human pain reports had a placebo or untreated comparison group.

See the sources (6)

• Promoted for injury recovery. The FDA’s BPC-157 review records clinics promoting it for injuries, wounds, tendons and ligaments.
• Knee pain: in one small report, 11 of 12 people who received BPC alone said their pain improved.
• Bladder pain: a separate report on 12 women also described symptom improvements.
• Neither had a placebo or untreated comparison group. Feeling better matters, but without a comparison it’s harder to separate the treatment’s effect from natural recovery, expectations or other care.
• There are also older controlled studies described in conference abstracts. So saying it’s never been tested in people would be wrong. Saying those records settle the recovery claims would go too far, too.
• A new registry record from a sponsor in Shenzhen had no results posted as of October 2, 2026.
• Safety: the FDA has flagged concerns about compounded BPC-157, including immune reactions, impurities and limited safety information.

• FDA BPC-157 review (clinic promotion, PDF pages 23–24)

It’s a modified version of a growth factor. Research about ordinary IGF-1 doesn’t automatically tell us what this altered version will do.

Some research is on the full protein, thymosin beta-4, not the small fragment the FDA discusses as TB-500. A dry-eye trial of the full protein didn’t clearly beat placebo on its two main measures.

See the sources (4)

• Sold, like BPC-157, for injury recovery.
• The FDA describes TB-500 as a seven-amino-acid fragment of thymosin beta-4.
• One trial tested eye drops containing the full protein for dry eye. It didn’t clearly beat placebo on its two main measures: eye discomfort and a staining test of the eye’s surface. Some secondary measures improved.
• That doesn’t test whether a fragment repairs a sports injury.
• A new registry record from a sponsor in Shenzhen had no results posted as of October 2, 2026.

• ClinicalTrials.gov NCT07487363 (TB-500, sponsor-submitted, no results posted as of October 2, 2026)
• 2026 primer describing how it’s promoted · PubMed 41476424

Tested on skin after laser treatment: no clear advantage on objective measures of redness, wrinkles or skin quality, but users rated their skin more favorably.

See the sources (3)

• A copper peptide promoted for skin and anti-aging.
• The small study put GHK-copper skin-care products on skin after CO2 laser resurfacing.
• Objective measures (redness, wrinkles, overall skin quality): no clear advantage. Patient ratings: more favorable.
• That doesn’t establish what injecting it would do.
• A new registry record from a sponsor in Shenzhen had no results posted as of October 2, 2026.

• ClinicalTrials.gov NCT07437586 (GHK-Cu, sponsor-submitted, no results posted as of October 2, 2026)
• 2020 paper on GHK as an anti-aging peptide · PubMed 35083444

Check for CB4211, a related experimental compound. Its trial registration describes testing safety and how the drug behaves in the body. That record isn’t a result for MOTS-c itself.

See the sources (4)

• A peptide your own mitochondria make, promoted for metabolism.
• The CB4211 record describes a randomized, placebo-controlled study of safety, tolerability and how the drug behaves in the body, in healthy non-obese adults and people with fatty liver disease.
• That record isn’t a result for MOTS-c itself.
• A new registry record from a sponsor in Shenzhen had no results posted as of October 2, 2026.

• ClinicalTrials.gov NCT07505745 (MOTS-c, sponsor-submitted, no results posted as of October 2, 2026)
• 2026 review describing how it’s promoted · PubMed 41966639

Epitalon and epithalamin aren’t the same substance; the FDA treats them as different. Combining their papers makes the evidence look tidier than it is.

See the sources (2)

• Promoted for aging. The FDA describes online clinics and concierge services promoting it as anti-aging.
• Epithalamin is a polypeptide complex extracted from the pineal gland. Epitalon is a synthetic tetrapeptide (four amino acids).
• Research on one doesn’t automatically transfer to the other.

• FDA advisory committee slides (anti-aging promotion, PDF page 100)

The developer reported that its large phase 2 trial found no statistically clear weight-loss advantage over placebo. Research existed. That result didn’t establish a benefit.

See the sources (3)

• A fragment of human growth hormone, promoted for fat loss. The FDA’s AOD-9604 review records weight-loss and body-fat promotion.
• An older safety report describes six controlled human trials.
• In 2007 the developer announced that weight loss compared with placebo in its large trial was too low to reach statistical significance.

• FDA AOD-9604 review (weight-loss promotion, PDF page 20)

One stroke study reported faster improvement in everyday-activity scores with Semax during rehabilitation. That doesn’t establish better focus or memory in healthy people.

See the sources (2)

• A nasal spray promoted for focus and memory. The FDA describes online Semax offerings promoted for attention and memory.
• The human finding comes from patients recovering from ischemic stroke, during rehabilitation.
• Those findings deserve to be described. We need the patients, the comparison and the actual outcome, not just the peptide’s name.

• FDA advisory committee slides (Semax promotion, PDF page 141)

A small study in patients reported anxiety relief similar to the anti-anxiety drug it was compared with. We need the patients, the comparison and the actual outcome, not just the peptide’s name.

See the sources (1)

• Often sold alongside Semax, promoted for anxiety and calm.
• The study: patients with generalized anxiety disorder and neurasthenia. It reported anxiety relief similar to medazepam, the anti-anxiety drug it was compared with.
• A finding in patients is worth knowing. It isn’t proof for every calm or focus claim made online.

A registry record describes adding it to light treatment for vitiligo, but its own description calls it an example record. We can’t treat that as a verified trial.

See the sources (3)

• Sold online as a tanning injection.
• We found five ClinicalTrials.gov records naming the same sponsor and a hospital in Shenzhen. They cover BPC-157, TB-500, GHK-copper, MOTS-c and Melanotan II.
• This one describes adding Melanotan II to light treatment for vitiligo, a condition that causes patches of skin to lose color. Its own description calls it an example record.
• These records are sponsor-submitted. As of October 2, 2026, none had results posted. Registration alone doesn’t mean a study has finished, or that its treatment worked.
• An estimated date for collecting the main data isn’t a promise that results will be published that day.

• 2012 paper on melanotan injections and sunbed use · PubMed 23785612

One large trial in people with sepsis found no clear evidence that it reduced deaths over 28 days. That doesn’t settle every possible use. It does show why a big trial and a positive result are different things.

See the sources (3)

• A peptide from the thymus, often promoted for immune support. FDA warning letters document sellers promoting it for immune health.
• The trial (TESTS, BMJ 2025) was multicentre, double-blind and placebo-controlled, in adults with sepsis, a life-threatening response to infection.
• It found no clear evidence that thymosin alpha-1 reduced deaths from any cause over 28 days.

• FDA warning letter to Paradigm RE, December 7, 2020 (immune-health promotion)

In a placebo-controlled trial in people with obesity, it led to substantial weight loss. It’s still an experimental drug without FDA approval, and a trial result doesn’t verify a bottle sold online.

See the sources (2)

• Research here matches a widely discussed goal: weight loss.
• In the 2023 phase 2 trial in people with obesity, retatrutide led to substantial weight loss compared with placebo. The most common side effects were digestive problems, including nausea and diarrhea.
• As of October 2, 2026, it remains an experimental drug without FDA approval. The FDA says retatrutide isn’t a component of any approved drug.
• A result from a controlled trial doesn’t verify the contents of a separate bottle sold online.

• FDA: concerns with unapproved GLP-1 drugs used for weight loss (retatrutide status, checked October 2, 2026)

As Egrifta, it’s approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. The label says it isn’t a treatment for general weight-loss management.

See the sources (3)

• Sold online for fat loss and growth hormone.
• Tesamorelin is the active ingredient in Egrifta, approved to reduce excess abdominal fat in adults with HIV and lipodystrophy, a condition that changes how the body stores fat.
• The label specifically says it isn’t indicated for weight-loss management.
• An approval belongs to a particular medicine and a particular use. It doesn’t spread to every bottle with a matching name.

• 2026 review describing online use · PubMed 42395176

As Vyleesi, it’s approved for certain premenopausal women with a diagnosed sexual-desire disorder. That isn’t a blanket approval for any product sold as a libido booster.

See the sources (2)

• Also called bremelanotide. Sold online as a libido booster; an FDA warning letter (August 2026) documents one seller’s libido pitch.
• Vyleesi is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
• An approval belongs to a particular medicine and a particular use. It doesn’t spread to every bottle with a matching name.

• FDA warning letter to TXP Innovations (Tex Peptides), August 24, 2026